Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2023-05-16 00:00:00 ET · period of report 2023-05-12 · accession 0001562180-23-004169 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-16 | 2023-05-12 | AKBA | Hadas Nicole R. | SVP, CLO | A - Grant | $0.00 | +100.0K | 387.5K | +35% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-12 | A | A | 100,000 | $0.00 | 387,530 | D | — | — | (F1) The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. |